International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Meanwhile, AZ is working to expand Fasenra, Tezspire and IL-33 candidate tozorakimab into COPD. The company believes there is value in bringing multiple biologics to the indication. “Sometimes ...

Tozorakimab: Demonstrating potential benefits of tozorakimab to reduce excess inflammation in IL-33 driven diseases • FRONTIER phase II programme: results from four studies across asthma and COPD ...

Bermekimab (IL-1α neutralization), PF-06650833 (IRAK4 inhibitor blocking downstream signaling), Tadekinig alfa (Th17 balance modulation via IL-18BP), Astegolimab and Tozorakimab (targeting IL-33 ...

WILMINGTON, Del., May 13, 2025--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at ...